Strs Ohio Makes New Investment in ADMA Biologics Inc $ADMA

Key Points

• Strs Ohio invested approximately $1.31 million in ADMA Biologics, purchasing 65,900 shares of the biotechnology company during the first quarter.
• ADMA Biologics reported a 13.8% increase in revenue year-over-year, achieving $121.98 million for the quarter, while beating the consensus earnings estimate by $0.01.
• The company's stock price has a one-year range of $13.50 to $25.67, indicating significant volatility and potential for growth.

Strs Ohio purchased a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 65,900 shares of the biotechnology company's stock, valued at approximately $1,307,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Invesco Ltd. lifted its position in ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after acquiring an additional 1,570,649 shares during the last quarter. Nuveen LLC bought a new stake in ADMA Biologics in the first quarter valued at about $93,543,000. American Century Companies Inc. grew its stake in ADMA Biologics by 12.7% during the first quarter. American Century Companies Inc. now owns 4,252,362 shares of the biotechnology company's stock worth $84,367,000 after buying an additional 478,800 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in ADMA Biologics by 7.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock worth $59,211,000 after buying an additional 207,097 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its stake in ADMA Biologics by 114.9% during the first quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company's stock worth $58,460,000 after buying an additional 1,575,363 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.25 during trading hours on Friday, reaching $15.91. 8,438,957 shares of the company were exchanged, compared to its average volume of 3,009,029. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The stock's fifty day moving average is $17.22 and its two-hundred day moving average is $18.93. The company has a market cap of $3.80 billion, a price-to-earnings ratio of 18.50 and a beta of 0.54. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period in the prior year, the business earned $0.13 earnings per share. ADMA Biologics's quarterly revenue was up 13.8% on a year-over-year basis. Sell-side analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.